CA2772336A1 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and compositions for diagnosis and prognosis of renal injury and renal failure Download PDF

Info

Publication number
CA2772336A1
CA2772336A1 CA2772336A CA2772336A CA2772336A1 CA 2772336 A1 CA2772336 A1 CA 2772336A1 CA 2772336 A CA2772336 A CA 2772336A CA 2772336 A CA2772336 A CA 2772336A CA 2772336 A1 CA2772336 A1 CA 2772336A1
Authority
CA
Canada
Prior art keywords
plasma concentration
measured
subject
cohort
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2772336A
Other languages
English (en)
French (fr)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of CA2772336A1 publication Critical patent/CA2772336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2772336A 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure Abandoned CA2772336A1 (en)

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
US23811509P 2009-08-28 2009-08-28
US23813409P 2009-08-28 2009-08-28
US23812909P 2009-08-28 2009-08-28
US23812709P 2009-08-28 2009-08-28
US23811809P 2009-08-28 2009-08-28
US23812009P 2009-08-28 2009-08-28
US23812109P 2009-08-28 2009-08-28
US23812309P 2009-08-28 2009-08-28
US23812509P 2009-08-28 2009-08-28
US23812809P 2009-08-28 2009-08-28
US61/238,128 2009-08-28
US61/238,134 2009-08-28
US61/238,127 2009-08-28
US61/238,120 2009-08-28
US61/238,118 2009-08-28
US61/238,123 2009-08-28
US61/238,115 2009-08-28
US61/238,129 2009-08-28
US61/238,121 2009-08-28
US61/238,125 2009-08-28
US24399309P 2009-09-18 2009-09-18
US24399709P 2009-09-18 2009-09-18
US24400209P 2009-09-18 2009-09-18
US24399109P 2009-09-18 2009-09-18
US61/243,991 2009-09-18
US61/243,993 2009-09-18
US61/243,997 2009-09-18
US61/244,002 2009-09-18
PCT/US2010/046910 WO2011025917A1 (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
CA2772336A1 true CA2772336A1 (en) 2011-03-03

Family

ID=43628398

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2772336A Abandoned CA2772336A1 (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Country Status (9)

Country Link
US (2) US20120315649A1 (cg-RX-API-DMAC10.html)
EP (3) EP2470905B1 (cg-RX-API-DMAC10.html)
JP (2) JP5775874B2 (cg-RX-API-DMAC10.html)
CN (2) CN104483488A (cg-RX-API-DMAC10.html)
AU (1) AU2010286559B2 (cg-RX-API-DMAC10.html)
CA (1) CA2772336A1 (cg-RX-API-DMAC10.html)
HK (1) HK1208074A1 (cg-RX-API-DMAC10.html)
NZ (2) NZ598712A (cg-RX-API-DMAC10.html)
WO (1) WO2011025917A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) * 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
IN2012MN02812A (cg-RX-API-DMAC10.html) 2010-06-23 2015-05-22 Astute Medical Inc
CN105137085A (zh) * 2010-06-23 2015-12-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
WO2012102963A1 (en) * 2011-01-26 2012-08-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
EP2503340A1 (en) * 2011-03-22 2012-09-26 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Diagnostic marker for relapsing primary idiopathic focal segmental glomerulosclerosis
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
US20150168422A1 (en) * 2011-05-12 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
EP2834638B1 (en) * 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN104569417B (zh) * 2013-10-12 2016-06-01 广州瑞博奥生物科技有限公司 一种用于早期诊断急性肾损伤的抗体芯片试剂盒
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11143658B2 (en) 2015-05-12 2021-10-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11435364B2 (en) * 2018-05-24 2022-09-06 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
CN117825674A (zh) * 2023-12-28 2024-04-05 南方医科大学南方医院 用于评估肝病预后的分子标志物及诊断试剂盒
CN121186383B (zh) * 2025-11-24 2026-03-13 华中科技大学 慢性肾病的蛋白质标志物的筛选及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
IL143892A0 (en) * 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
WO2002048329A2 (en) * 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2002081515A1 (fr) * 2001-04-03 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Proteine de liaison de facteur de croissance de type insuline
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
US7416854B2 (en) * 2004-01-22 2008-08-26 Promega Corporation Luminogenic and nonluminogenic multiplex assay
US20090215046A1 (en) * 2004-01-27 2009-08-27 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays methods of use thereof for diagnosis of colon cancer
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP4991547B2 (ja) * 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
US7141382B1 (en) * 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
WO2006102979A2 (de) * 2005-03-31 2006-10-05 Johannes Gutenberg-Universität Mainz Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen
WO2006116622A2 (en) * 2005-04-27 2006-11-02 Emiliem Novel methods and devices for evaluating poisons
TW200716764A (en) * 2005-05-02 2007-05-01 Genenews Inc Bladder cancer biomarkers and uses thereof
EP1904657B1 (en) * 2005-06-08 2011-05-25 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US8129135B2 (en) * 2006-04-24 2012-03-06 Medizinische Universität Wien Method for diagnosing cardiovascular diseases
DK2115477T3 (en) * 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
WO2008122670A2 (en) * 2007-04-10 2008-10-16 Integragen Human diabetes susceptibility tnfrsf10b gene
US20110183434A1 (en) * 2008-01-17 2011-07-28 Myles Wolf Diagnostic methods and kits using fibroblast growth factor-23
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
JP2015212704A (ja) 2015-11-26
US20150204892A1 (en) 2015-07-23
HK1172691A1 (en) 2013-04-26
EP2470905A1 (en) 2012-07-04
EP3151005A1 (en) 2017-04-05
EP2470905A4 (en) 2013-08-14
AU2010286559A1 (en) 2012-04-05
US20120315649A1 (en) 2012-12-13
CN102792161A (zh) 2012-11-21
EP2470905B1 (en) 2015-01-07
EP2894473A1 (en) 2015-07-15
CN102792161B (zh) 2014-11-12
AU2010286559B2 (en) 2015-01-22
JP2013503344A (ja) 2013-01-31
EP2894473B1 (en) 2016-09-21
HK1208074A1 (en) 2016-02-19
CN104483488A (zh) 2015-04-01
NZ598712A (en) 2014-05-30
WO2011025917A1 (en) 2011-03-03
NZ624609A (en) 2015-12-24
JP6054481B2 (ja) 2016-12-27
JP5775874B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
AU2009285550B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2470905B1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2740923A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2735590A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2774223A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2743253A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2846602A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2788826A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2751435A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
CA2965153A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2751424A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2496942B1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2751430A1 (en) Diagnosis and prognosis of renal injury and renal failure
CA2770393A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2788829A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2773905A1 (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
CA2865559A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2789147A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2880793A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2014270083A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20200064360A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2865563A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2988980A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2014277715A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2015203434A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150727

FZDE Discontinued

Effective date: 20170829